Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Ozempic and Wegovy boxes made by Novo Nordisk at the pharmacy in London on March 8, 2024.
Holly Adams | Reuters
Sale Novo nordiskIn the second quarter, the Blokbast, which scattered the weight, grew in the second quarter, the company reports in its latest report because it promised to reduce the cost after losses.
Revenues from its blockbuster Wegovy atmession drug rose by 67% to 19.53 billion Danish taps three months before the end of June, just below 20 billion Danish crane forecasts in the LSEG poll.
The shares decreased by 1.2% to 10:07 am in London (5:07 am et).
The total sales volume increased by 13% compared to last year with constant rates to 76.86 billion Danish crowns ($ 11.92 billion) during this period, only ahead of $ 76.6 billion of Danish analysts.
The quarterly net profit amounted to 26.5 billion Danish crowns, against 26.6 billion Danish cranes.
Danish drug manufacturer once again confirmed his view of the full year after he reduced his recommendations on the weaker sales forecast in the second half for Wegovy last week and his diabetes treatment.
Now the company expects an annual sales growth by 8% to 14% at constant courses, as well as annual revenue growth by 10% to 16%.
Novo Nordisk also stated that it would reduce the costs and exacerbate its commercial attention after the company’s stock price took over last week, continuing long -term decreases after the June 2024 peak.
Novo Nordisk.
“We take measures to further exacerbate our commercial implementation, as well as ensure the efficiency of our costs, continuing to invest in the future growth,” said President and CEO Lars Frugard Jorgensen in a statement.
The CEO, which is included in the Masar Mike Dustddar, which comes into force on Thursday, said last week that he involves the role of “feeling relevant, laser focus on high performance and rigid determination for Novo Nordisk to strive for the goal higher than when it is done.”
The Fruergaard Jørgensen surprise occurred in May when the company struggled with softer sales in the US amid enhanced competition from immersed drug manufacturers and a large competitor Eli Lily. Disappointing results of the trial The next generation of Cagrisema was added to their next -generation drug candidate.
A wider pharmaceutical industry faces the prospect of significant tariffs for the White House – which US President Donald Trump said on Tuesday, which can runs up to 250% – And the pressure from the administration to reduce drug prices.
White House on Thursday said President Trump was Sent letters Up to 17 major pharmaceutical firms, including Novo Nordisk, setting the steps they have to take to reduce the price of US prescription drugs to the level of the “most supportive nation” (MFN) by September 29.
